YL-15293 / Shanghai YingLi Pharma - LARVOL DELTA

Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (clinicaltrials.gov) - P1/2 | N=150 | Enrolling by invitation | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Apr 2023 ➔ Apr 2024

Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • MSI • PD-1 • PD-L1

Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (clinicaltrials.gov) - P1/2 | N=150 | Enrolling by invitation | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting ➔ Enrolling by invitation | N=90 ➔ 150 | Trial primary completion date: Nov 2022 ➔ Apr 2023

Enrollment change • Enrollment open • Metastases • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • MSI • PD-1 • PD-L1

A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov) - P1/2; N=90; Not yet recruiting; Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Clinical • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • MSI